DRREDDY — earnings call
The transcript as filed. Every paragraph is addressable: its link names the page and the position it sits at in the call.
Prepared remarks
Moderator · Conference Operator
Ladies and gentlemen, good day and welcome to the Q4 FY22 Earnings Conference Call of Dr. Reddy's Laboratories Limited.
As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes.
Should you need assistance during the conference call, please signal an operator by pressing * then 0 on your touchtone phone.
Please note that this conference is being recorded.
I now hand the conference over to Mr. Amit Agarwal - Head of Investor Relations.
Thank you and over to you, sir.
Amit Agarwal
Thank you.
A very good morning and good evening to all of you and thank you for
Questions and answers
Erez Israeli
Thank you, Parag.
Good morning and good evening to everyone.
As Prasad highlighted, the FY22 has been quite a challenging year, yet it is being fulfilling.
We rose to the challenges and have been able to deliver a steady and sustained performance.
We have revisited our strategy to cater to the new opportunities and mitigate risk.
Our financial strength of strong balance sheet creates an opportunity for us to grow in the current business environment.
Let me take you through some of the key highlights of the year.
1.
Strong growth across branded markets of India and emerging markets, 2.
Steady growth across generics market, we regained milestone revenue of $1 billion in North America generics, 3.
Improved market share in most of our major markets, 4.
EBITDA and ROCE in the range of our aspirational targets, 5.
Generation of strong free cash flow leading to a net surplus of more than $200 million, 6.
Entered high-growth space of medical cannabis business in Germany through acquisition of Nimbus Health, 7.
Exclusive collaboration with Novartis for in-licensing of key brands in India market, and Dr. Reddy's Laboratories Limited May 19, 2022 8.
Significant progress made in our digitalization and sustainability journey.
Additionally, we continue to focus on productivity, while simultaneously making investments to strengthen our pipeline and capabilities.
While our core business of generic and API will continue to drive growth in the near to midterm, that is what we call Horizon-I, we are encouraged to witness several incremental opportunities such as scaling up of our existing small sized businesses and creation of new business models for the long-term growth, that is for us Horizon-II.
Our financial strength allow us to grow and invest for both Horizon-I and Horizon-II businesses.
Now, let me take you through the key business highlights for the Q4 as well as the full year of 22.
Please note that all references to the numbers in this section are in respective local currencies.
Our North America generics business recorded sales of $265 million for the quarter with a strong growth of 11% year-over-year and 7% on sequential business.
On a full year basis, we recorded sales of 1,003 million with a growth of 6% over the previous years.
This growth was largely led by key new product launches such as, Icosapent Ethyl Softgels and Vasopressin for injection.
We are able also to grow market share for many of our existing products which helped to partially mitigate the impact of the price erosion.
We launched three new products during the quarter and overall, 17 products during the year.
We expect the launch momentum to further improve in FY23. Our Europe business recorded sales of €53 million this quarter with a strong year-on- year growth of 17% and sequential quarter growth of 11%.
On a full year basis, the sales were € 192 million and has grown by 8%, driven by new product launches.
During the quarter, we launched four products in Germany, two products each in Italy and Spain and 1 each in UK and France.
During the full year, we had 34 new launches across our markets in Europe.
We expect this strong growth momentum to continue in FY23. Our emerging markets business recorded sales of Rs.
1,201 crores with a year-on-year growth of 36% and a sequential quarter growth of 4%.
On a full year basis, emerging market sales has been Rs.
4,567 crores and grew by 30%.
We launched 16 new products during the quarter and 86 new products during the year across various countries of the emerging markets.
Within the emerging market segment, the Russia business in quarter 4 grew by 87% on a year-to-year basis and 62% on a quarter-to-quarter basis in constant currency.
In FY22, Russia business grew by 38% in constant currency.
This strong performance in Dr. Reddy's Laboratories Limited May 19, 2022 Russia was partially led by divestment income of two brands and higher Q4 sales on account of stocking up which we expect to normalize during the coming quarter.
The current war situation in Russia and Ukraine raised several business uncertainties and significant fluctuation in the currency rates.
We have managed the situation very well and ensured the safety of our employees, continued the business operation and financially securing the near term with effective hedging.
Our India business recorded sales of Rs.
969 crores with a year-over-year growth of 15% and a sequential decline of 6%.
On a full year basis, our sales was Rs.
4,196 crores with a strong growth of 26%.
During the quarter, we launched 8 new products in the Indian market.
As per the IQVIA report of March 2022, we are at number 11 on a monthly basis.
India remains a priority market and we are committed to continue to grow this business at a healthy rate.
Our PSAI business recorded sales of $100 million with a year-over-year decline of 8% and sequential growth of 3%.
On a full year basis, the sales were $411 million with a decline of 5%.
During the year, there has been normalization in the channel customer stocking level after uptick seen in FY21. We believe that the customer stock levels are now back to pre-COVID level and we should witness steadier growth in the business in FY23. On the R&D front, our focus has been on building a global pipeline of value accretive products, including several generic injectables and biosimilars.
We are also selectively investing in few NCE product candidates.
While the number of product filings in the current year has been slightly lower, however, we are on track to accelerate this in FY23. Additionally, we are prepared to leverage our balance sheet strength to invest in value accretive inorganic moves.
I would like to remind that there are several factors which have an impact on the short- term performance of the company, including evolving geopolitical situation and higher commodity price.
However, I am confident that we will emerge stronger with every challenge.
We do see opportunities in the current situation and are readjusting our strategy to cater to the new opportunities for future goals.
In the coming month, we will be holding our Investor Day and take you through the growth levers for Horizon-I, Horizon-II and our approach and goals towards ESG.
With this, I would like to open the floor for questions and answers.
Moderator · Conference Operator
Thank you very much.
We will now begin the question-and-answer session.
The first question is from the line of Ankush from Axis Securities.
Please go ahead.
Dr. Reddy's Laboratories Limited May 19, 2022
Ankush
Sir, my question is about the US business, so how much of the sale is contributed by the new launches for FY22 and last year?
Erez Israeli
So, the growth is assessed by two factors: one, our new products and I noted two of them Icosapent and Vasopressin as well as a growth in market share of existing products and both of them contribute significantly to the growth.
Ankush
So, can I say that it is a $1,000 million sales in the US market for the full year that the new launches has contributed, how much sales new launches has contributed, if you quantify, sir?
And how many new products that we are looking to launch next year?
Parag Agarwal
So, overall, as you know, the price erosion in the US business is in double digits and that is more than offset by the new product launches and the share gains.
So, without disclosing any specific numbers, I can confirm that the new product launches would contribute in double digit to the overall revenue.
Ankush
And sir, how many new products that we are looking to launch next year?
Parag Agarwal
So, the momentum will continue.
This year, as you know, in North America, we launched 17 products.
We expect to launch about 20 to 25 new products in FY23.
Ankush
So, the last one, what is the strategy for the Indian market, how we are looking at the launch of new products, basically the growth in the Indian market, sir?
Erez Israeli
We will continue to launch similar numbers of products like this year.
At the same time, the main growth in India will come; first, growing of the brands that we are investing behind that will continue to generate the main growth in the markets, the second inorganic moves that we already disclosed as well as additional moves that we are working on as we speak.
In addition to that, we will have new products that will come as part of the pattern which are about similar numbers that we had this year.
In addition to that, this is what we call Horizon-I.
As part of Horizon-II, we are going to have additional moves in the area, but we will disclose more during the Investor Day, but this will be in the area of activity that we watch which is our outpatient initiatives as well in the areas of nutrition, biologics activities and digital.
So, overall, India is a major market for us and it will continue to be a focus market for us for many many years to come.
Moderator · Conference Operator
Thank you.
The next question is from the line of Kunal Dhamesha from Macquarie.
Please go ahead.
Dr. Reddy's Laboratories Limited May 19, 2022
Kunal Dhamesha
So, the first question is related to the COVID contribution for FY22, if you can give a broader idea, what contribution in terms of revenue was from the COVID or related products, especially on India side and emerging market side?
Parag Agarwal
So, the contribution, as you know, both India and emerging markets have grown this year in strong double digits.
A good amount of this growth came from COVID, but even after excluding the impact of COVID portfolio, both these markets still recorded double-digit growth.
So, overall, I would say, for the company as a whole, the contribution of COVID product sales overall is less than 4%.
Kunal Dhamesha
And for the India market, barring the inorganic activity which is when it happens it happens, what is our organic growth target for FY23?
And if you can just broadly give the growth drivers in terms of pricing, volume and I think new products we are already aware, but would pricing be a very significant driver for us this year?
Erez Israeli
As you know, we are not guiding the industry level of details, but we are expecting India to continue to grow organically in double-digit also next year.
Kunal Dhamesha
And the second question is on the capital expenditure for FY23, this year we had some good amount of CAPEX, I think for the Europe facility, what would be the guidance for FY23?
Parag Agarwal
For FY23, we expect the capital expenditure overall to be at similar levels, around somewhere between Rs.
1,500 crores to Rs.
1,700 crores.
Kunal Dhamesha
And I believe that would mean some additional facilities, so for which geography and for which injectable or oral solids, which kind of dosage form we are looking at?
Erez Israeli
We are not anticipating the need for additional facilities.
The investment is primarily in the facilities that we have.
FTO-11 which is our coming up injectable facility that we are investing in it, actually quite a lot in the last couple of years will be one place of, so the CAPEX will grow as well as in the biologics and digital.
This will be the main focus of the investment.
Moderator · Conference Operator
Thank you.
The next question is from the line of Neha Manpuria from Bank of America.
Please go ahead.
Neha Manpuria
Erez, on the emerging market business; one, if I were to look at emerging markets ex Russia and Ukraine, that seems to have come off significantly for what we were doing in the first 3 quarters, I understand there is some amount of COVID contribution, is it fair to assume that the run rate that you have done in this quarter is the base on which Dr. Reddy's Laboratories Limited May 19, 2022 we will grow?
Or is there any one-off or deferment of shipment that we should keep in mind?
Erez Israeli
No one-offs in those markets.
These markets are growing very well and we will continue to grow in that level.
Just if you recall, we discussed our part of the strategy is to take our portfolio globally.
EM is actually doing it well, especially on the injectable side.
So, the EM will continue to grow, including smaller markets based on the leverage of that portfolio as well as local brands, but primarily the leverage.
This indeed a nice contributor to the growth.
Neha Manpuria
And on Russia, normalizing for the stocking up that we would have seen in the quarter, in the recent weeks have you seen any change in the demand patterns there or sales there that you would like to highlight?
Or should we assume that Russia would remain on the double-digit growth path that we have seen in the last year?
Erez Israeli
So, I believe that we will see some normalization of what we discussed, but overall, we believe that Russia is an opportunity, especially as some of the players will not invest in marketing the products over time and we will continue to operate this as usual.
What we don't know, of course, is what will be the impact on the overall economy of Russia.
This is, of course, something that we have to see.
Neha Manpuria
And my last question is on margins, so if I were to adjust all the one-offs, we did about 21% margin in the quarter, I understand there is Revlimid that is coming, generic Revlimid that is coming through, but core margins, excluding Revlimid, is this the base or given the investments that we have planned, do you think margin expansion from here would be tough ex Revlimid?
Erez Israeli
We believe that the number is higher than the number that you mentioned.
It is actually 24% and we want to sustain the neighborhood of the guidance that we gave in the past.
So, we are comfortable with the 25:25 and we think that we will be in that area as we want to take whatever additional resources we have for investment in the future.
So, we are maintaining our ability and we believe that we can for both maintaining this level of profitability as well as to invest in the future, especially in our case in Horizon- II.
Neha Manpuria
And just to clarify that, you maintain the level of profitability even excluding Revlimid?
Erez Israeli
We are not guiding with and without because naturally, first, we don't and second, I wish I knew exactly what will happen, so you know that, but let us say, long term, no matter what will be the scenario for Revlimid, we are absolutely aiming for the same level.
Dr. Reddy's Laboratories Limited May 19, 2022
Moderator · Conference Operator
Thank you.
The next question is from the line of Surya Patra from Philip Capital.
Please go ahead.
Surya Patra
Sir, first question is on the cost front, so despite all the challenges what we have seen, we have managed to deliver strong gross margins and all that, so going ahead given what you see, do you think any cost challenges that we will be facing incrementally given the supply shortness that is likely to be seen given the Chinese lockdown and all that?
That is one and secondly, you have talked about the Phase-1 growth what we have already seen and you are designing and devising a Phase-2 kind of growth sales for Dr. Reddy with new product launches and specialty offerings and all that, so whether in the Phase-2, we will see a kind of challenging phase in the initial period in terms of cost given the higher expenditure around the development and all that?
So, something on the cost front, how would that be really shaping up?
And how would that be having the impact on the overall margins for Dr. Reddy?
Erez Israeli
So, like everybody else in the industry, we are facing some increase of cost, whether it is commodity prices as well as in things that are related to logistics, transportation and stuff like that and it is unfortunately not the first quarter that we see that it is something that has gradually built up since COVID, but we absolutely saw intensifying situation like that also recently.
We were able to mitigate most of it by, first of all, having a very effective supply chain, so we are not dependent on any specific territories or whether it is geography or specific vendors and we are able to maintain the competitive fulfillment.
Our logistics is primarily done by sea and less by air and this is allowing us to mitigate some of those challenges.
We are moving into over time to renewable energy.
This is mostly mid to long term natural initiative.
This is enabling us also to deal with the energy potential future challenges.
So, we may see a certain, let us say, the cost may fluctuate from quarter-to-quarter, but long term, I believe that we are well set to mitigate those challenges.
Surya Patra
The second question is on the US growth front, sir, as you have been continuously mentioning that double-digit kind of price erosion that is a kind of the norm in the US business front and in the recent past, our trend towards US also has moderated because of their prioritizing the non-US market for growth, so given that and the continuing price erosion scenario, so is it fair to believe that ex of Revlimid we may see a flattish kind of a US performance?
Any sense on that, sir?
I am not asking about any guidance. but?
Erez Israeli
So, our US business will grow and from time to time we will have launches, in addition the other activities that we do and that is what we also did in the last 11 quarters.
So, I believe that we grew 9 out of the last 11 quarters and this is before even Revlimid and this is likely to continue.
Because of timing of those launches, we may see also Dr. Reddy's Laboratories Limited May 19, 2022 fluctuation in the sales in the United States, but overall, I believe that on the annual basis, we will grow in net sales in the coming years.
In addition to that, we are investing in building platforms that are outside of the business model that allow us also to grow long term so we want to stay in America, we believe in America, America will continue to be an important market for us.
In the generics segment, likely it will not grow like we will grow outside of the US, but other growth drivers that we are now working on absolutely will continue to grow as in America in the same way that we are growing in other places in long term.
Surya Patra
Just last one, sir, on the inorganic growth trend, when you mentioned about that, are you talking about only inorganic growth within India or it is even you are open for international activity also, if it is that, then the areas that you would be interested in, if you can just share something there?
Erez Israeli
We are open to inorganic moves in every one of our spaces.
In terms of preference, India is absolutely a preference and in terms of what kind of this development, we prefer product acquisitions as a complementary move to the spaces that we put as a focus in our strategy.
So, that most of our inorganic activities were around products.
We are naturally disclosing those that are relatively big, but we are all the time working to strengthen the portfolio also through inorganic and in-licensing activities.
We are also preferring not to make a kind of a big acquisition, but rather a complementary that will give us the relevant opportunities, stuff like this, but we want to remain primarily an organic growth organization.
Moderator · Conference Operator
Thank you.
The next question is from the line of Nikhil Mathur from HDFC Mutual Fund.
Please go ahead.
Nikhil Mathur
So, my first question is around the Russian market, in line with the global sanctions that the West applied on Russia, we came across many media articles in which many global innovator companies, they are either withdrawing from Russian market or they are curtailing their operations there, so have you had any discussions with the procurement ecosystem in the Russian market that this could be a fairly structured and substantial opportunity for Dr. Reddy's given your legacy presence in the market?
Obviously, there are challenges currently but still, I mean, could this emerge as a long- term three to four year structured opportunity for the company?
Erez Israeli
So, we do see that as an opportunity for us.
We cannot discuss now any specific discussions, but it is absolutely one of the avenues that we are discussing as we speak.
Nikhil Mathur
And second question is on the broader US outlook, so two questions related to the US, one is on the opportunity in the next 3 years, excluding Revlimid, how do you see the Dr. Reddy's Laboratories Limited May 19, 2022 addressable opportunity in terms of brands losing exclusivity next year versus the preceding period?
Erez Israeli
Without Revlimid, we do see it in the same way that we saw this year.
We have, in addition to that, as Parag mentioned 20-25 new launches which will not be as sizable as Revlimid, but will contribute to us and I believe that the price erosion will continue.
So, in that way, I don't think that things will change dramatically for us.
Nikhil Mathur
And then, one final question is for the US market, just now in one of the earnings calls concluded for one of your peers, this question was asked, I am just repeating that question again; progressively, quarter-on-quarter we have seen the margins and the return ratios getting depressed in the US market and now with the added pressure of cost inflation, any color can you give as to tell what time can this pain continue before rationality kicks in?
I mean, in the past we have seen global companies withdrawing, but do you think that even the Indian companies which today are at $100, $200 million kind of a sales pace in the US, there also might have to pull out or curtail their ambition in the US market, do you think we reached to stage where that pain has to be somehow mitigated?
G V Prasad
I will answer this question.
I think the US market will always remain price competitive.
There has always been pricing pressure.
It is not new and it will not end.
It will continue.
It depends on how well you choose your portfolio, how well you execute and how competitive you are to continue to establish your presence there and we are taking a number of steps to strengthen our portfolio, lower our costs, improve our market share and we hope to continue to grow in the US.
Erez Israeli
The US will stay important market for us and as I mentioned, we want to be stronger in the generic space, but we were also working on moves outside of that area.
Nikhil Mathur
I think, Erez, I mean, I kind of understand that.
I mean, we have read your strategy quite clear, I was just hoping to get some comments on how do you see the competition reacting to the current state of affairs in the US market?
I mean, it is fine, if you want to reserve your comments but?
Erez Israeli
I believe that this will continue.
That is how we see it.
We don't see significant changes coming up or disruption to the current state of this.
Moderator · Conference Operator
Thank you.
The next question is from the line of Prakash Agarwal from Axis Capital.
Please go ahead.
Dr. Reddy's Laboratories Limited May 19, 2022
Prakash Agarwal
A couple of questions, sir, first, on the COVID-related products, you mentioned this 4% contribution, but is there any write-offs which we might have taken at the inventory level in the full year or the quarter?
Parag Agarwal
Any inventory provisions relating to COVID, there are some write-offs, but they are not significant overall and the overall inventory levels we are carrying for our COVID products are also not material.
We have obviously stocked up adequately to meet any potential demand, but the overall levels are not material.
Prakash Agarwal
When you say not material, I would understand it would be under 1%.
Parag Agarwal
I wouldn't put a number to it.
It is not material in the overall context of our business.
We will not confirm or deny it.
Prakash Agarwal
And secondly, on the proprietary business that we have built over years, I understand most of the assets are largely either outlicensed or couple of them have been discontinued, so going forward, what is the income stream for this?
One is, I understand the milestones, but we don't have anything in the channel for future new out-licensing, would that be correct understanding?
G V Prasad
On the specialty side, there is nothing significant out there.
There are some single-digit income streams which will continue in single digit million dollars, but beyond that, there is nothing much left.
Prakash Agarwal
Because if I am not wrong, this has contributed significantly in terms of out-licensing which has flown down from gross margin to EBITDA and has contributed significantly at the margins, correct me if I am wrong and it is not in future then, given your commentary on raw material prices and etc., cost inflation, this would be an extra margin pressure point for us, would that be correct?
Erez Israeli
Let me clarify.
First of all, on specialty, we have two parts.
We have those products that we discussed that were in the former 505(b)(2) for the United States.
As you stated rightly so, most of them were licensed or discontinued and as we speak, we are enjoying certain levels of royalties and as well as future milestones that may come and then, we will enjoy the income of those milestones at the time that it will come, especially on product like E7777, etc. We have also activities that are related to NCE.
This is what I mentioned in my script that we have selectively invested now in certain anti-cancer products as part of our subsidiary of Aurigene discovery and this is more of a long-term and in that frame we are also licensing and have collaborations in the United States with partners and we are working both to license those products as well as maybe one day in the future to build ourselves.
In terms of contribution to the margin Dr. Reddy's Laboratories Limited May 19, 2022 and stuff like that, I think we had indeed fee from licensing in Q2 and in Q4 there was no activity as such.
Prakash Agarwal
The last part was not clear; would it impact some margins?
Erez Israeli
I don't know in margin.
There are no activity, therefore no impact in the margins.
Maybe I did not get your question, what effective on margin and by when?
Amit Agarwal
So, in the past, what Erez mentioned is basically in quarter 4, there was no licensing income we have received.
So, the quarter 4 numbers are without any margin benefit.
Prakash Agarwal
Perfect and that run rate is also like the Rs.
69 crores is the ongoing proprietary sales, so that can continue.
Amit Agarwal
Proprietary plus Aurigene, it is combined sales.
Prakash Agarwal
So, that can continue and if there is lumpiness, that might not continue.
G V Prasad
There will be lumpiness.
It is not smooth curve, because these are milestone-driven, deal- driven.
Prakash Agarwal
And lastly, sir, on the two good products that you have, so Vascepa and Vasopressin, so these have seen market share inching up, but not to the level that one could have expected, so is there a scale-up issue or you have already achieved a fair share and we are not able to see in the data base?
Erez Israeli
We believe that we have a good share in this product.
G. V. Prasad
And we can't give that granular numbers to you.
Prakash Agarwal
Have you achieved a fair share, sir, on Vascepa of 15%, 13% to 15%?
Erez Israeli
We have a very good share on these products.
Prakash Agarwal
And since it is a recent launch, Vasopressin, this is still under the scale up phase, would that be correct understanding?
Erez Israeli
We have also a good share on this product.
Moderator · Conference Operator
Thank you.
The next question is from the line of Sameer Baisiwala from Morgan Stanley.
Please go ahead.
Dr. Reddy's Laboratories Limited May 19, 2022
Sameer Baisiwala
Sir, most of my questions have been asked but just a couple of them more.
One is, what is the current exposure to Ukraine market?
And are we holding any receivables over there?
Erez Israeli
So, the level of exposure is not material and there is no any material adverse event or significant adverse events that we anticipate in the future.
Sameer Baisiwala
And Erez, you mentioned a couple of times that for the US market, you are putting in some effort outside of the generic business, so can you elaborate on that?
Was it the NCE effort or is it something else?
Erez Israeli
We will elaborate more in the Investor Day, but we are, as we speak, exploring other channels that are not exposed to the current business model in the United States, of course, high level of price erosion that needs to be mitigated by products, so we are exploring and we have been dealing with opportunities that let us say are not part of that business model.
Sameer Baisiwala
And the other question, Erez, is two efforts that you have put in, in India, one is Sputnik vaccine and the other is outpatient online healthcare platform, so if you can update us on both of these?
Erez Israeli
Sure, on Sputnik, the main effort is on Sputnik Light.
We got approval for Sputnik Light as a vaccine and as a booster for Sputnik vaccine and we are now conducting a trial that we will have the results in the next coming weeks as a vaccine for other vaccines in India and we hope to obtain approval for that.
This will allow us to compete on the entire Indian market potential if we get approval.
The second effort that we did on Sputnik is that we repatriate the product to India.
So, all the activities on Sputnik are now in India, we are not dependent on Russia in any shape and form for that effort.
On Svaas we are scaling up.
We are adding more and more cities in the metros and it is a scale-up mode.
So, far it looks very promising, but naturally it is an early stage for these initiatives, but it looks very promising in the service and we are so far quite positive.
Moderator · Conference Operator
Thank you.
The next question is from the line of Vishal Manchanda from Nirmal Bang.
Please go ahead.
Vishal Manchanda
With respect to the two brands that you divested in Russia and CIS, Ciprolet and Levolet, can you share what is their contribution since sales from these brands would not recur going forward?
Parag Agarwal
Sorry, I couldn't catch the question.
Dr. Reddy's Laboratories Limited May 19, 2022
Erez Israeli
What is the contribution of the divestment in Russia, Levolet and Ciprolet,
Amit Agarwal
Sales of these brands.
Parag Agarwal
That would be about Rs.
50 crores to Rs.
60 crores per annum.
Vishal Manchanda
And even without these brands coming in, contributing next year you would grow double digit in these markets?
Parag Agarwal
Yes.
Vishal Manchanda
And just one more on Rituxan biosimilar.
Two things; one, when do you expect to file that?
And second, whether you are trying to do an interchangeable on that?
Amit Agarwal
Rituximab filing timeline.
Erez Israeli
So we are looking for Rituximab as a potential 2024 event.
I am talking about calendar 2024.
Vishal Manchanda
And are you attempting an interchangeable on that?
Amit Agarwal
Interchangeability, yes
Erez Israeli
Yes, of course.
Vishal Manchanda
So, substitutable, is that right?
Erez Israeli
This is a biosimilar that should be competitive with the rest of the biosimilars of Rituximab.
Vishal Manchanda
And just one more on China, can you share how many approvals have you got under the QCE framework so far?
And how many of those have been commercialized?
Parag Agarwal
This year we received, we actually filed for 11 products and we received 3 approvals during the year and overall, in FY23, we are expecting to launch about 7 products.
Vishal Manchanda
How many, sir?
Parag Agarwal
Seven.
Moderator · Conference Operator
Thank you.
The next question is from the line of Nitin Agarwal from DAM Capital.
Please go ahead.
Dr. Reddy's Laboratories Limited May 19, 2022
Nitin Agarwal
Sir, my question is one on Voveran, what opportunities do we see on this product given the fact that this molecule has been under some growth pressures in the past?
Parag Agarwal
Which molecule?
Nitin Agarwal
Voveran that we acquired from Novartis for the Indian market?
Erez Israeli
So, we see that as an important opportunity for us.
At first, we will repatriate it to our Indian facility and we believe that our cost structure will allow us to be competitive.
And the second, it is an area of focus for us, the diabetics as well as cardiovascular, the area of chronic, the segment of disease was always a focus for us and this is an opportunity to bring a familiar brand to the physicians that we are visiting anyway and we believe that our margins will enable us to even grow these molecules in the future.
Nitin Agarwal
And secondly, Parag, in the press release you have called out for the gross margin pressure, some amount of inventory provisions, can you just give us some sense on what would have been the quantum of these inventory provisions that would have hurt your EBITDA margin, the gross margin this quarter?
Parag Agarwal
So, overall, I would say the impact on the gross margin is not significant.
It will be less than 50 basis points from the inventory provision.
Moderator · Conference Operator
Thank you.
The next question is from the line of Vinod B from InCred Capital.
Please go ahead.
Vinod B
Most of my questions are answered, just a follow-up on Russia, so could you make a few comments about how the business has changed before the war started and after that, especially in terms of logistics, payment, etc., so are you able to get products across into Russia?
And how are you managing the payments, mechanism out of Russia, etc.?
Erez Israeli
So, let us start with the basic.
We are shipping products to Russia and we are getting money from Russia and the logistics within Russia is similar to what was before.
We had to adjust our channels, the airlines or other logistics means to shift to Russia, but we do not see any issues with that, we have done all consolidations for that and as for the payment and the stuff like that, actually we saw no disruption as we speak.
In terms of within the market, we are not aware of anyone that actually left the market, probably there will be less investment in the market, but we are not aware of anyone that actually left or changed significantly the competitive landscape.
It is probably something that will happen, but as we speak, we do not see it.
Dr. Reddy's Laboratories Limited May 19, 2022
Moderator · Conference Operator
Thank you.
Ladies and gentlemen, this was the last question for today.
I would now like to hand the conference over to Mr. Amit Agarwal for closing comments.
Amit Agarwal
Thank you everyone for joining us today for the earnings call.
In case of any further questions, please get in touch with the Investor Relations team.
Thank you.